Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 17/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 12/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9200266 | 0.90 | NR1I2 (0.73) | NR1I2CYP3A4CYP2D6S1PR1S1PR3 | |
| SCHEMBL13623352 | 0.87 | NR1I2 (0.83) | NR1I2CYP3A4CYP2D6 | |
| SCHEMBL9202945 | 0.85 | NR1I2 (0.67) | NR1I2CYP3A4CYP2D6S1PR1S1PR3 | |
| SCHEMBL8120288 | 0.81 | NR1I2 (0.67) | NR1I2CYP3A4CYP2D6L3MBTL1 | |
| SCHEMBL8874925 | 0.80 | NR1I2 (0.72) | NR1I2CYP3A4CYP2D6S1PR1S1PR3 | |
| SCHEMBL9201720 | 0.80 | CYP3A4 (0.52) | NR1I2CYP3A4CYP2D6S1PR1S1PR3 | |
| SCHEMBL8127081 | 0.79 | NR1I2 (0.71) | NR1I2CYP3A4CYP2D6S1PR1S1PR3 | |
| SCHEMBL8138320 | 0.79 | NR1I2 (0.68) | NR1I2CYP3A4CYP2D6S1PR1L3MBTL1 | |
| SCHEMBL8132900 | 0.79 | NR1I2 (0.68) | NR1I2CYP3A4CYP2D6S1PR1L3MBTL1 | |
| SCHEMBL9205929 | 0.78 | NR1I2 (0.57) | NR1I2CYP3A4CYP2D6S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291990-A1 | OXADIAZOLYL-PHENOXYALKYLISOXAZOLES, COMPOSITIONS THEREOF AND METHODS FOR THEIR USE AS ANTI-PICORNAVIRAL AGENTS | RHODES GERALD | 2009-11-26 | — | — | US | disclosed |
| US-7429606-B2 | Oxadiazolyl-phenoxyalkylisoxazoles, compositions thereof and methods for their use as anti-picornaviral agents | VIROPHARMA INCORPORATED (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291990-A1 | OXADIAZOLYL-PHENOXYALKYLISOXAZOLES, COMPOSITIONS THEREOF AND METHODS FOR THEIR USE AS ANTI-PICORNAVIRAL AGENTS | PLEC, CPSF7, CPSF1 | NR1I2 1884/4885CYP3A4 771/4885CYP2D6 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.